MX2016000393A - Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. - Google Patents
Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.Info
- Publication number
- MX2016000393A MX2016000393A MX2016000393A MX2016000393A MX2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A
- Authority
- MX
- Mexico
- Prior art keywords
- lysine
- microbial transglutaminase
- protein modifications
- chemoenzymatic
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
- C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/08—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
Abstract
La presente invención se refiere a métodos y reactivos para utilizarse en la modificación de sitio selectivo de proteínas que tienen residuos de lisina con péptidos funcionalizados utilizando una reacción mediada por transglutaminasa microbiana quimioenzimática. Las proteínas funcionalizadas se pueden utilizar para estudio o usos terapéuticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845273P | 2013-07-11 | 2013-07-11 | |
US201462016044P | 2014-06-23 | 2014-06-23 | |
PCT/US2014/046409 WO2015006728A2 (en) | 2013-07-11 | 2014-07-11 | Site-specific chemoenzymatic protein modifications |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016000393A true MX2016000393A (es) | 2016-10-26 |
Family
ID=51298955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000393A MX2016000393A (es) | 2013-07-11 | 2014-07-11 | Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. |
Country Status (12)
Country | Link |
---|---|
US (4) | US9359400B2 (es) |
EP (2) | EP3019515B1 (es) |
JP (1) | JP6739333B2 (es) |
KR (1) | KR20160040556A (es) |
CN (1) | CN105593238B (es) |
AU (1) | AU2014286990A1 (es) |
BR (1) | BR112016000585A2 (es) |
CA (1) | CA2918076A1 (es) |
EA (1) | EA201690205A1 (es) |
ES (1) | ES2756526T3 (es) |
MX (1) | MX2016000393A (es) |
WO (1) | WO2015006728A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2918076A1 (en) * | 2013-07-11 | 2015-01-15 | Novartis Ag | Site-specific chemoenzymatic protein modifications |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
CN108602878B (zh) * | 2015-12-18 | 2022-06-28 | 卫材R&D管理有限公司 | C端赖氨酸缀合免疫球蛋白 |
WO2017173415A2 (en) | 2016-03-31 | 2017-10-05 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
MX2018015331A (es) | 2016-06-10 | 2019-08-16 | Eisai R&D Man Co Ltd | Inmunglobulinas conjugadas con lisina. |
EP4309670A2 (en) | 2016-09-02 | 2024-01-24 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
WO2023244963A2 (en) * | 2022-06-16 | 2023-12-21 | The General Hospital Corporation | Bicyclononyne reagents for cell imaging |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
DE4022267C2 (de) * | 1990-07-12 | 1994-09-15 | Degussa | N-Acyldipeptide und deren Verwendung |
JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
ATE212233T1 (de) | 1992-08-31 | 2002-02-15 | Baxter Healthcare Sa | Impfstoffe gegen neisseria meningitidis gruppe c |
US5508191A (en) | 1993-07-05 | 1996-04-16 | Takeda Chemical Industries, Ltd. | Mutant strains of agrobacterium for producing β-1,3-glucan |
EP0777726B1 (en) | 1994-08-26 | 2006-06-07 | Novozymes A/S | Microbial transglutaminases, their production and use |
WO1996010089A1 (fr) | 1994-09-29 | 1996-04-04 | Ajinomoto Co., Inc. | Modification d'un peptide et d'une proteine |
EP0871712B1 (en) | 1995-01-19 | 2003-08-27 | Novozymes A/S | Transglutaminases from oomycetes |
JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
EP0815833B1 (en) * | 1996-06-24 | 2003-04-09 | Givaudan SA | Malodour preventing agents |
EP0950665A4 (en) | 1996-09-26 | 2004-05-06 | Ajinomoto Kk | PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
EP1054998A1 (en) | 1998-01-20 | 2000-11-29 | Pericor Science, Inc. | Transglutaminase linkage of agents to tissue |
US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
KR100947751B1 (ko) | 2001-01-23 | 2010-03-18 | 아벤티스 파스퇴르 | 다가 수막구균 폴리사카라이드-단백질 접합체 백신 |
US7605175B2 (en) | 2001-03-02 | 2009-10-20 | Gpc Biotech Ag | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
PT1490409E (pt) | 2002-03-26 | 2009-04-03 | Novartis Vaccines & Diagnostic | Sacáridos modificados possuindo uma estabilidade melhorada em água |
GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
KR20070052747A (ko) | 2004-09-10 | 2007-05-22 | 도레이 가부시끼가이샤 | 의약품제제 |
AU2005302269B2 (en) | 2004-11-01 | 2011-05-19 | The Brigham And Women's Hospital, Inc. | Modified streptococcal polysaccharides and uses thereof |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
AU2006259080A1 (en) * | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of growth hormone |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
CN101809032A (zh) * | 2007-08-24 | 2010-08-18 | 诺沃-诺迪斯克有限公司 | 用于选择性修饰蛋白质的方法 |
US8426179B2 (en) * | 2007-08-30 | 2013-04-23 | Northwestern University | Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
DE102007044296A1 (de) * | 2007-09-17 | 2009-03-19 | Hans-Lothar Prof. Dr. Fuchsbauer | Strukturmodulator von Proteinen |
US8137925B2 (en) * | 2007-11-09 | 2012-03-20 | Massachusetts Institute Of Technology | Methods and compositions for protein labeling using lipoic acid ligases |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
WO2010002042A1 (ja) * | 2008-07-04 | 2010-01-07 | 国立大学法人 九州大学 | タンパク質ラベル化用酵素基質 |
ES2401965T3 (es) * | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
US8853151B2 (en) | 2009-06-30 | 2014-10-07 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
US20110020837A1 (en) | 2009-07-07 | 2011-01-27 | Universiteit Utrecht Holding B.V. | Method for isolating or identifying a target protein interacting with a lipid in a cell |
EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
EP2563753B9 (en) * | 2010-04-27 | 2016-07-06 | SynAffix B.V. | Fused cyclooctyne compounds and their use in metal-free click reactions |
EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
WO2012004419A2 (en) | 2010-07-09 | 2012-01-12 | Université De Bretagne Occidentale | Modular construction of lipophospholipids |
CN103298949A (zh) | 2010-10-29 | 2013-09-11 | 生命科技公司 | 生物素衍生物 |
JP6105477B2 (ja) | 2010-11-05 | 2017-03-29 | ライナット ニューロサイエンス コーポレイション | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 |
CA2823837A1 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
CA2814953A1 (en) | 2010-12-13 | 2012-06-21 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
FR2981352B1 (fr) * | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
MX2014006594A (es) | 2011-12-01 | 2015-09-16 | Angiochem Inc | Compuestos de enzimas lisosomales apuntados. |
JP5509440B2 (ja) * | 2012-06-22 | 2014-06-04 | 国立大学法人九州大学 | タンパク質−核酸複合体の製造方法および標的物の検出方法 |
AU2014283185B2 (en) * | 2013-06-21 | 2019-05-02 | Innate Pharma | Enzymatic conjugation of polypeptides |
CA2918076A1 (en) * | 2013-07-11 | 2015-01-15 | Novartis Ag | Site-specific chemoenzymatic protein modifications |
-
2014
- 2014-07-11 CA CA2918076A patent/CA2918076A1/en not_active Abandoned
- 2014-07-11 EA EA201690205A patent/EA201690205A1/ru unknown
- 2014-07-11 AU AU2014286990A patent/AU2014286990A1/en not_active Abandoned
- 2014-07-11 BR BR112016000585A patent/BR112016000585A2/pt not_active Application Discontinuation
- 2014-07-11 ES ES14748350T patent/ES2756526T3/es active Active
- 2014-07-11 WO PCT/US2014/046409 patent/WO2015006728A2/en active Application Filing
- 2014-07-11 JP JP2016525817A patent/JP6739333B2/ja active Active
- 2014-07-11 CN CN201480046805.8A patent/CN105593238B/zh active Active
- 2014-07-11 EP EP14748350.7A patent/EP3019515B1/en active Active
- 2014-07-11 EP EP19187438.7A patent/EP3613755A1/en not_active Withdrawn
- 2014-07-11 KR KR1020167003053A patent/KR20160040556A/ko not_active Application Discontinuation
- 2014-07-11 MX MX2016000393A patent/MX2016000393A/es unknown
- 2014-07-11 US US14/329,758 patent/US9359400B2/en active Active
-
2016
- 2016-05-02 US US15/144,397 patent/US20160237116A1/en not_active Abandoned
-
2018
- 2018-11-29 US US16/204,557 patent/US10975120B2/en active Active
-
2021
- 2021-04-12 US US17/228,284 patent/US20220089639A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN105593238A (zh) | 2016-05-18 |
EP3613755A1 (en) | 2020-02-26 |
JP6739333B2 (ja) | 2020-08-12 |
US20190300570A1 (en) | 2019-10-03 |
ES2756526T3 (es) | 2020-04-27 |
EP3019515B1 (en) | 2019-08-21 |
US20150017192A1 (en) | 2015-01-15 |
JP2016526574A (ja) | 2016-09-05 |
EP3019515A2 (en) | 2016-05-18 |
US9359400B2 (en) | 2016-06-07 |
US20160237116A1 (en) | 2016-08-18 |
AU2014286990A1 (en) | 2016-02-11 |
US10975120B2 (en) | 2021-04-13 |
CN105593238B (zh) | 2020-09-08 |
KR20160040556A (ko) | 2016-04-14 |
BR112016000585A2 (pt) | 2018-03-20 |
WO2015006728A2 (en) | 2015-01-15 |
CA2918076A1 (en) | 2015-01-15 |
US20220089639A1 (en) | 2022-03-24 |
WO2015006728A3 (en) | 2015-03-12 |
EA201690205A1 (ru) | 2016-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016000393A (es) | Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. | |
PH12015501651A1 (en) | Antibody constructs for cdh19 and cd3 | |
TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
AU2017261625B2 (en) | Non-natural consensus albumin binding domains | |
EA201691669A1 (ru) | Связывающие сывороточный альбумин домены фибронектина iii типа | |
MX2018011503A (es) | Proteinas de union y metodos de uso de las mismas. | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
PH12016500482A1 (en) | Combination therapy with an anti-ang2 antibody and a cd40 agonist | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
MX2016008667A (es) | Inmunoglobulina con fab en tandem y usos de esta. | |
MY186864A (en) | Fusion immunomodulatory proteins and methods for making same | |
SG10201808523RA (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
IN2015DN01404A (es) | ||
WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
MX2015012872A (es) | Anticuerpos anti-tau y metodos de uso. | |
NZ766444A (en) | Factor h binding protein variants and methods of use thereof | |
PH12018501443A1 (en) | Methods of administering hepcidin | |
MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
MX2013012791A (es) | Analogos del factor b del complemento y sus usos. | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
MX353464B (es) | Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles. | |
TW201613981A (en) | Compositions and methods for the diagnosis of rheumatoid arthritis | |
WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
MX2015012281A (es) | Proteinas de union a tnf mejoradas. |